Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
The return on equity (ROE) is N/A as of the fiscal period ended Monday, March 31, 2025.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q3 FY2024 (2025-03-31): -114.49%.
RETURN ON EQUITY (ROE)
N/A
RETURN ON EQUITY (ROE) AVG TTM
N/A
RETURN ON EQUITY (ROE) AVG 3Y
N/A
RETURN ON EQUITY (ROE) AVG 5Y
N/A
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Market Cap
$5.22M
Return on Equity (ROE)
-156.94%
TTM Avg
-121.17%
3Y Avg
-95.34%
5Y Avg
-84.55%
Market Cap
$5.20M
Return on Equity (ROE)
-42.05%
TTM Avg
-32.76%
3Y Avg
-25.11%
5Y Avg
-45.26%
Market Cap
$5.24M
Return on Equity (ROE)
-225.57%
TTM Avg
-289.16%
3Y Avg
-245.03%
5Y Avg
-192.04%
Market Cap
$5.29M
Return on Equity (ROE)
-156.77%
TTM Avg
-655.11%
3Y Avg
-353.82%
5Y Avg
-293.10%
Market Cap
$5.35M
Return on Equity (ROE)
-154.08%
TTM Avg
-205.06%
3Y Avg
-23.78%
5Y Avg
-114.15%
Market Cap
$5.03M
Return on Equity (ROE)
-248.66%
TTM Avg
-110.63%
3Y Avg
-33.84%
5Y Avg
-33.84%
Market Cap
$5.02M
Return on Equity (ROE)
-163.18%
TTM Avg
-235.11%
3Y Avg
-195.15%
5Y Avg
-161.13%
Market Cap
$5.02M
Return on Equity (ROE)
-351.30%
TTM Avg
-321.98%
3Y Avg
-228.03%
5Y Avg
-177.46%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Lunai Bioworks Inc. (LNAI) | $5.21M | N/A | N/A | N/A | N/A |
| Pulmatrix, Inc. (PULM)vs › | $5.22M | -156.94% | -121.17% | -95.34% | -84.55% |
| Gelteq Limited Ordinary Shares (GELS)vs › | $5.20M | -42.05% | -32.76% | -25.11% | -45.26% |
| Intelligent Bio Solutions Inc. (INBS)vs › | $5.24M | -225.57% | -289.16% | -245.03% | -192.04% |
| Alzamend Neuro Inc (ALZN)vs › | $5.29M | -156.77% | -655.11% | -353.82% | -293.10% |
| Soligenix, Inc. (SNGX)vs › | $5.35M | -154.08% | -205.06% | -23.78% | -114.15% |
| Basel Medical Group Ltd Ordinary Shares (BMGL)vs › | $5.03M | -248.66% | -110.63% | -33.84% | -33.84% |
| Lexaria Bioscience Corp. (LEXX)vs › | $5.02M | -163.18% | -235.11% | -195.15% | -161.13% |
| Imunon, Inc. (IMNN)vs › | $5.02M | -351.30% | -321.98% | -228.03% | -177.46% |
| Liminatus Pharma, Inc. Class A Common Stock (LIMN)vs › | $5.00M | -4165.92% | 61.14% | -23.12% | -18.15% |
ROE
N/A
ROA
-1301.0%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2025-03-31 | -114.49% |
| 2024-12-31 | -195.44% |
| 2024-09-30 | -160.73% |
